Market capitalization | $602.68m |
Enterprise Value | $470.17m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.58 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-40.20m |
Free Cash Flow (TTM) Free Cash Flow | $-30.10m |
Cash position | $147.31m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
8 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:
8 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.65 -0.65 |
49%
49%
|
|
EBITDA | -40 -40 |
8%
8%
|
EBIT (Operating Income) EBIT | -40 -40 |
10%
10%
|
Net Profit | -35 -35 |
24%
24%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
Head office | United States |
CEO | Yuval Cohen |
Employees | 19 |
Founded | 2009 |
Website | www.corbuspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.